Navigation Links
Cell Therapeutics Exercises Its Option to Sell Interest in Zevalin Joint Venture to Spectrum Pharmaceuticals for $18 Million
Date:2/20/2009

patent and administrative governmental authorities, competitive factors, technological developments, and costs of developing, producing and selling Zevalin. There is also a risk that even if label expansion of Zevalin is approved, it may not result in a significant market increase for the drug due to the presence of other treatment options, failure to gain market acceptance and other factors. Additionally, the closing of the sale option and receipt of the purchase price assumes that the company will be able to satisfy all of the closing conditions and that Spectrum fulfills its legal obligations to timely deliver the purchase price. Disposition of our interest in Zevalin may not reduce our expenses to the extent as currently projected. You should also review the risk factors listed or described from time to time in the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's most recent filings on Forms 10-K, 8-K, and 10-Q. Except as may be required by law, CTI does not intend to update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.

    Media Contact:
    Dan Eramian
    T: 206.272.4343
    C: 206.854.1200
    E: media@ctiseattle.com
    www.CellTherapeutics.com/press_room

    Investors Contact:
    Ed Bell
    T: 206.272.4345
    Lindsey Jesch Logan
    T: 206.272.4347
    F: 206.272.4434
    E: invest@ctiseattle.com
    www.CellTherapeutics.com/investors


'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... 2014 Best Sanitizers, Inc., a leader ... processing industry, is asking industry professionals to prepare for ... the E2 soap they’re currently using to the Best ... Hand hygiene is critical to fighting cross-contamination and ... Six key criteria are identified to evaluate the effectiveness ...
(Date:8/28/2014)... “This kit has an improved extraction efficiency and provides ... ppb,” said Mark Tess, PhD, Mycotoxin Product Manager for Charm ... and USDA-GIPSA inspection agencies that have a need to detect ... in a matter of minutes with nothing but our equipment ... and grain before accepting it, but they no longer have ...
(Date:8/28/2014)... devices in spintronics, an electronic which is not ... also on their spin and the spin-related magnetism. ... magnetic signals and vice versa. Recently, the research ... of Physics at Johannes Gutenberg University Mainz in ... Japan, has for the first time realised a ...
(Date:8/28/2014)... 28, 2014 The ability for organizations ... that will allow individuals to perform at the highest ... for employers looking to compete in this post–recession era. ... this trend, as the sector increasingly focuses on the ... which will have real results on the organization's development ...
Breaking Biology Technology:Best Sanitizers, Inc. Asks Food Industry Professionals: With Fall Harvest On the Way, Is Your E2 Hand Soap Up to the Task? 2A new, tunable device for spintronics 2A new, tunable device for spintronics 3Klein Hersh International Leads Philadelphia Area Life Science Industry in Company Culture 2Klein Hersh International Leads Philadelphia Area Life Science Industry in Company Culture 3
... diaDexus, Inc. (OTC Bulletin Board: DDXS ... commercialization of patent-protected in vitro diagnostic products ... the company, formerly known as VaxGen, Inc. and traded ... (VXGN), has been renamed diaDexus, Inc. diaDexus, common stock ...
... and latest developments ... ... --> ... are keyed by longUrl, so we need to grab the first one. for (var r in data.results) { first_result ...
... Medicago Receives Regulatory Approval and Commences Phase II Clinical Testing of its Avian Influenza Vaccine ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... = ""; BitlyCB.alertResponse = function(data) { var s = ,; var first_result; // Results are keyed by longUrl, so ...
Cached Biology Technology:diaDexus Announces Name Change From VaxGen 2diaDexus Announces Name Change From VaxGen 3NEURO-BIOTECH CORPORATION: Updates and latest developments 2NEURO-BIOTECH CORPORATION: Updates and latest developments 3NEURO-BIOTECH CORPORATION: Updates and latest developments 4NEURO-BIOTECH CORPORATION: Updates and latest developments 5NEURO-BIOTECH CORPORATION: Updates and latest developments 6NEURO-BIOTECH CORPORATION: Updates and latest developments 7NEURO-BIOTECH CORPORATION: Updates and latest developments 8NEURO-BIOTECH CORPORATION: Updates and latest developments 9Medicago Receives Regulatory Approval and Commences Phase II Clinical Testing of its Avian Influenza Vaccine 2Medicago Receives Regulatory Approval and Commences Phase II Clinical Testing of its Avian Influenza Vaccine 3Medicago Receives Regulatory Approval and Commences Phase II Clinical Testing of its Avian Influenza Vaccine 4Medicago Receives Regulatory Approval and Commences Phase II Clinical Testing of its Avian Influenza Vaccine 5Medicago Receives Regulatory Approval and Commences Phase II Clinical Testing of its Avian Influenza Vaccine 6Medicago Receives Regulatory Approval and Commences Phase II Clinical Testing of its Avian Influenza Vaccine 7Medicago Receives Regulatory Approval and Commences Phase II Clinical Testing of its Avian Influenza Vaccine 8
(Date:8/29/2014)... is available in German . ... in the natural nitrogen cycle on Earth and in ... were thought to depend on nitrite as their source ... Holger Daims, a microbiologist at the University of Vienna, ... as an alternative source of energy. The oxidation of ...
(Date:8/29/2014)... - The rise of the Tibetan plateau -- the ... is important for both its profound effect on climate ... published in GSA Bulletin , Katharine Huntington and ... thermometry -- using modern and fossil snail shells to ... southwestern Tibet. , Views range widely on the ...
(Date:8/28/2014)... available in German . ... its name to a striking pattern of blue stripes alternating ... reflective silvery cells, and yellow cells emerge during growth in ... a multilayered mosaic to compose the characteristic colour pattern. ... have to interact to form proper stripes, the embryonic origin ...
Breaking Biology News(10 mins):Hydrogen powers important nitrogen-transforming bacteria 2Hydrogen powers important nitrogen-transforming bacteria 3Snails tell of the rise and fall of the Tibetan Plateau 2Snails tell of the rise and fall of the Tibetan Plateau 3Snails tell of the rise and fall of the Tibetan Plateau 4Snails tell of the rise and fall of the Tibetan Plateau 5Snails tell of the rise and fall of the Tibetan Plateau 6Snails tell of the rise and fall of the Tibetan Plateau 7How the zebrafish gets its stripes 2How the zebrafish gets its stripes 3
... the Robarts Research Institute at The University of Western ... used a unique genetically-modified mouse line to reveal a ... led by Marco Prado, Robert Gros and Vania Prado ... how the decreased release of the neurotransmitter acetylcholine, a ...
... Cancer Institute have further developed a potential new treatment ... cancer cells, removing them from the body. The treatment, ... using samples from human cancer patients. The results appear ... are primarily interested in developing an effective method to ...
... (Boston) Boston University School of Medicine (BUSM) ... physiology, with joint appointments in biomedical engineering and medicine, ... Lipids. This award is being bestowed by ... in the application of nuclear magnetic resonance methods to ...
Cached Biology News:Genetically-modified mice reveal another mechanism contributing to heart failure 2Magnetic nanoparticles show promise for combating human cancer 2
EDTA, 0.5 M solution, 100 ml. Ethylene diaminetetraacetic acid.Sterile, nuclease-free. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Biochemicals ....
Recombinant Mouse TGF-beta RII/(human) Fc Chimera, CF...
Recombinant Mouse Noggin...
... Deacetylase (HDAC) Antibody Sampler Kit Kit ... Catalog #2062, 40 ul Histone Deacetylase 3 ... Deacetylase 4 (HDAC4) Antibody, Catalog #2072, 40 ... #2082, 40 ul Histone Deacetylase 6 (HDAC6) ...
Biology Products: